701 related articles for article (PubMed ID: 7702398)
1. Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus.
Atta MS; Lim KL; Ala'deen DA; Powell RJ; Todd I
Ann Rheum Dis; 1995 Feb; 54(2):117-24. PubMed ID: 7702398
[TBL] [Abstract][Full Text] [Related]
2. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
Lim KL; Jones AC; Brown NS; Powell RJ
Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
[TBL] [Abstract][Full Text] [Related]
3. Significance of anti-entactin antibodies in patients with systemic lupus erythematosus and related disorders.
Saxena R; Sturfelt G; Nived O; Wieslander J
Ann Rheum Dis; 1994 Oct; 53(10):659-65. PubMed ID: 7979578
[TBL] [Abstract][Full Text] [Related]
4. Detection of autoantibodies to killer immunoglobulin-like receptors using recombinant fusion proteins for two killer immunoglobulin-like receptors in patients with systemic autoimmune diseases.
Matsui T; Otsuka M; Maenaka K; Furukawa H; Yabe T; Yamamoto K; Nishioka K; Kato T
Arthritis Rheum; 2001 Feb; 44(2):384-8. PubMed ID: 11229470
[TBL] [Abstract][Full Text] [Related]
5. [Anti-fibronectin autoantibodies in systemic lupus erythematosus, rheumatoid polyarthritis, and various viral or bacterial infectious diseases].
Henane T; Rigal D; Monier JC
Pathol Biol (Paris); 1986 Mar; 34(3):165-71. PubMed ID: 3517785
[TBL] [Abstract][Full Text] [Related]
6. Anti-tubulin-α-1C autoantibody in systemic lupus erythematosus: a novel indicator of disease activity and vasculitis manifestations.
Zhao X; Cheng Y; Gan Y; Jia R; Zhu L; Sun X
Clin Rheumatol; 2018 May; 37(5):1229-1237. PubMed ID: 29427009
[TBL] [Abstract][Full Text] [Related]
7. Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus. SLE Study Group.
Witte T; Hartung K; Matthias T; Sachse C; Fricke M; Deicher H; Kalden JR; Lakomek HJ; Peter HH; Schmidt RE
Rheumatol Int; 1998; 18(2):63-9. PubMed ID: 9782535
[TBL] [Abstract][Full Text] [Related]
8. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
[TBL] [Abstract][Full Text] [Related]
9. [The role of anti-nucleosome antibodies in systemic lupus erythematosus. Results of a study of patients with systemic lupus erythematosus and other connective tissue diseases].
Quattrocchi P; Barrile A; Bonanno D; Giannetto L; Patafi M; Tigano V; Ferlazzo B
Reumatismo; 2005; 57(2):109-13. PubMed ID: 15983634
[TBL] [Abstract][Full Text] [Related]
10. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.
Zandman-Goddard G; Blank M; Langevitz P; Slutsky L; Pras M; Levy Y; Shovman O; Witte T; Doria A; Rovensky J; Shoenfeld Y
Ann Rheum Dis; 2005 Dec; 64(12):1698-702. PubMed ID: 16014675
[TBL] [Abstract][Full Text] [Related]
11. Impaired urinary excretion of soluble IL-2 receptors in patients with systemic lupus erythematosus and rheumatoid arthritis.
Manoussakis MN; Germanidis GS; Drosos AA; Moutsopoulos HM
Lupus; 1992 Feb; 1(2):105-9. PubMed ID: 1301961
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus.
Wirestam L; Schierbeck H; Skogh T; Gunnarsson I; Ottosson L; Erlandsson-Harris H; Wetterö J; Sjöwall C
Arthritis Res Ther; 2015 Nov; 17():338. PubMed ID: 26596890
[TBL] [Abstract][Full Text] [Related]
13. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease.
Tzioufas AG; Tzortzakis NG; Panou-Pomonis E; Boki KA; Sakarellos-Daitsiotis M; Sakarellos C; Moutsopoulos HM
Ann Rheum Dis; 2000 Feb; 59(2):99-104. PubMed ID: 10666163
[TBL] [Abstract][Full Text] [Related]
14. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
15. Identification of streptococcal proteins reacting with sera from Behçet's disease and rheumatic disorders.
Cho SB; Lee JH; Ahn KJ; Cho S; Park YB; Lee SK; Bang D; Lee KH
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S31-8. PubMed ID: 20868568
[TBL] [Abstract][Full Text] [Related]
16. Decreased serum thrombospondin-1 and elevation of its autoantibody are associated with multiple exacerbated clinical manifestations in systemic lupus erythematosus.
Meng Y; Zhang M; Zhao X; Cheng Y; Jia R; Wang Y; Sun X
Clin Rheumatol; 2018 Oct; 37(10):2707-2714. PubMed ID: 29998369
[TBL] [Abstract][Full Text] [Related]
17. Human anti-alpha-enolase antibody in sera from patients with Behçet's disease and rheumatologic disorders.
Lee JH; Cho SB; Bang D; Oh SH; Ahn KJ; Kim J; Park YB; Lee SK; Lee KH
Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S63-6. PubMed ID: 19796536
[TBL] [Abstract][Full Text] [Related]
18. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus.
Italiani P; Manca ML; Angelotti F; Melillo D; Pratesi F; Puxeddu I; Boraschi D; Migliorini P
Arthritis Res Ther; 2018 Feb; 20(1):27. PubMed ID: 29422069
[TBL] [Abstract][Full Text] [Related]
19. [The autoantibody profile and disease activity in patients with systemic lupus erythematosus].
Horák P; Hermanová Z; Faltýnek L; Pospísil Z; Scudla V
Vnitr Lek; 1997 Oct; 43(10):639-44. PubMed ID: 9601876
[TBL] [Abstract][Full Text] [Related]
20. [Serum soluble interleukin 2 receptor levels in patients with diffuse connective tissue diseases].
Sun HY; Liu WL; Xiu HZ
Zhonghua Nei Ke Za Zhi; 1993 Aug; 32(8):528-30. PubMed ID: 8269781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
